As a heterodimeric glycoprotein, Clusterin is more abundant in the CSF of some neurodegenerative disease patients than in healthy controls, and could thus serve as a potential biomarker to differentiate Parkinson’s disease from dementia with Lewy bodies (Vranová et al., 2016). This evidence concerns the gene CLU and dementia.